Literature DB >> 11026109

Elevated anti-annexin V antibody levels in antiphospholipid syndrome and their involvement in antiphospholipid antibody specificities.

H Ogawa1, D Zhao, J S Dlott, G S Cameron, M Yamazaki, T Hata, D A Triplett.   

Abstract

To clarify the involvement of annexin V (ANX) in antiphospholipid antibody (APA) specificities, we studied antiANX antibodies (aANX) using 2 kinds of enzyme-linked immunosorbent assay plates (plain and gamma-irradiated) and anti-beta 2-glycoprotein I antibodies (a-beta 2GPI) in 53 patients with antiphospholipid syndrome (APS). The incidence of aANX IgG-positive results in the autoimmune APS group was significantly higher than that of healthy control subjects. However, we could not demonstrate a significantly higher incidence in the infection- or drug-induced group. Nor could we find an increased incidence of IgM isotype. When the 2 plates were compared, the discrepancies of positivity were demonstrated in both isotypes. We speculated that these discrepancies between the plate surfaces were attributed to the altered antigenicity of ANX. Although positivity of a-beta 2GPI was associated significantly with clinical manifestations, no significant associations were demonstrated between the incidence of aANX-positive results and clinical manifestations. We inferred that the involvement of aANX in the pathogenic mechanism of APS is unlikely.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11026109     DOI: 10.1309/298H-NLBU-E47G-8PYL

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  7 in total

1.  Evaluation of the clinical relevance of anti-annexin-A5 antibodies in Chinese patients with antiphospholipid syndrome.

Authors:  Shulan Zhang; Ziyan Wu; Jing Li; Xiaoting Wen; Liubing Li; Wen Zhang; Jiuliang Zhao; Fengchun Zhang; Yongzhe Li
Journal:  Clin Rheumatol       Date:  2016-12-21       Impact factor: 2.980

2.  Cross-reactivity between annexin A2 and Beta-2-glycoprotein I in animal models of antiphospholipid syndrome.

Authors:  R Weiss; A Bitton; L Nahary; M T Arango; I Benhar; M Blank; Y Shoenfeld; J Chapman
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

3.  Anticardiolipin antibodies in proliferative diabetic retinopathy: An additional risk factor.

Authors:  Maha Shahin; Amany M El-Diasty; Mohamed Mabed
Journal:  Saudi J Ophthalmol       Date:  2009-08-05

4.  Anti-annexin V antibodies in Takayasu's arteritis: prevalence and relationship with disease activity.

Authors:  N K Tripathy; N Sinha; S Nityanand
Journal:  Clin Exp Immunol       Date:  2003-11       Impact factor: 4.330

5.  Annexin V and anti-Annexin V antibodies: two interesting aspects in acute myocardial infarction.

Authors:  Mohammad Shojaie; Abdoreza Sotoodah; Shohre Roozmeh; Ensieh Kholoosi; Samira Dana
Journal:  Thromb J       Date:  2009-07-21

6.  Rational Laboratory Diagnostics of Antiphospholipid Antibodies: Anti-Cardiolipin, Anti-β2-Glycoprotein I, Anti-Prothrombin and Anti-Annexin V Antibodies.

Authors:  Bozic Borut; Sasa Cucnik; Natasa Gaspersic; Ales Ambrozic; Tanja Kveder; Blaz Rozman
Journal:  EJIFCC       Date:  2010-01-26

7.  Evaluation of the Diagnostic Value of Non-criteria Antibodies for Antiphospholipid Syndrome Patients in a Chinese Cohort.

Authors:  Chaojun Hu; Siting Li; Zhijuan Xie; Hanxiao You; Hui Jiang; Yu Shi; Wanting Qi; Jiuliang Zhao; Qian Wang; Xinping Tian; Mengtao Li; Yan Zhao; Xiaofeng Zeng
Journal:  Front Immunol       Date:  2021-09-10       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.